BriaCell Therapeutics (NSDQ:BCTX) announced today that it closed an underwritten public offering worth $25 million. Berkeley, Calif.-based BriaCell offered more than 4.85 million common units comprised of one share of common stock and one warrant to purchase one share of common stock priced at $4.25 per unit, according to a news release. Additionally, the offering […]
ICU Medical dips despite Street-beating Q4
ICU Medical (NSDQ:ICUI) shares took a slight hit today on fourth-quarter results that topped the consensus forecast. The San Clemente, Calif.-based infusion therapy and critical care technology developer posted profits of $26.1 million, or $1.21 per share, on sales of $320.5 million for the three months ended Dec. 31, 2020, for a 2.7% bottom-line gain on […]
8 drug delivery innovations you need to know
The drug delivery space has seen plenty of innovation over the years and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means. Among the […]
Axonics acquires Contura and its Bulkamid bulking agent for $235M
Axonics (NSDQ: AXNX) announced today that it acquired Contura and its flagship Bulkamid product for up to $235 million. London-based Contura’s Bulkamid is a urethral bulking agent for women with stress urinary incontinence (SUI). It is a next-generation hydrogel injected into the urethral wall in a minimally invasive office or outpatient facility procedure to restore the natural closing pressure […]
Kala Pharmaceuticals slides on missed Q4 projections
Kala Pharmaceuticals (NSDQ:KALA) shares dipped this morning on fourth-quarter results that came up short of the consensus forecast. The Watertown, Mass.-based company posted losses of -$31.1 million, or -55¢ per share, on sales of $2.2 million for the three months ended Dec. 31, 2020, for a more than $10 million bottom-line slide on sales growth […]
Tandem Diabetes Care skyrockets after hours on Street-beating Q4
Tandem Diabetes Care (NSDQ:TNDM) shares soared after hours today on fourth-quarter results that topped the consensus forecast. Shares of TNDM were up 12.9% at $103.04 per share after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.8%. The San Diego-based insulin delivery and […]
Insulet rises on Street-beating Q4 revenues
Insulet (NSDQ:PODD) shares rose before the market opened today on fourth-quarter results that beat the consensus revenue forecast. The Acton, Mass.-based wearable insulin delivery system developer posted losses of -$17.1 million, or -26¢ per share, on sales of $246.1 million for the three months ended Dec. 31, 2020, for a bottom-line slide into the red on […]
B. Braun Medical appoints new CFO
B. Braun Medical announced today that it appointed James Allen as a senior VP and as the company’s chief financial officer. Allen, a veteran of more than 30 years in finance and management within multiple industries and disciplines, will replace Bruce Heugel, who last year announced that he would retire after more than 20 years at […]
Re-Vana Therapeutics appoints new COO, VP of R&D
Re-Vana Therapeutics announced today that it appointed Michael Nash as chief commercial officer and David Shima as VP of R&D. Belfast, Northern Ireland-based Re-Vana’s two new executives are set to help the company develop its sustained-release therapies for ophthalmic indications, including neovascular age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and glaucoma, according to a […]
Pear Therapeutics touts cost-effectiveness of opioid use disorder treatment
Pear Therapeutics today touted analysis of its reSET-O therapeutic for opioid use disorder (OUD) that demonstrated cost-effectiveness. Boston-based Pear Therapeutics’ reSET-O is the first and only FDA-authorized prescription digital therapeutic for treating OUD, according to a news release. The analysis, published in Postgraduate Medicine, highlighted that reSET-O and treatment-as-usual (which includes transmucosal buprenorphine, face-to-face counseling […]